Kelly Maloney
Concepts (352)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 36 | 2023 | 267 | 5.690 |
Why?
| Down Syndrome | 6 | 2023 | 328 | 1.660 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2022 | 1385 | 1.550 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2023 | 65 | 1.480 |
Why?
| Asparaginase | 8 | 2020 | 28 | 0.980 |
Why?
| Burkitt Lymphoma | 2 | 2020 | 53 | 0.860 |
Why?
| Child | 65 | 2023 | 19033 | 0.790 |
Why?
| Consolidation Chemotherapy | 2 | 2019 | 8 | 0.770 |
Why?
| Leukemia, Myeloid, Acute | 5 | 2022 | 532 | 0.740 |
Why?
| Child, Preschool | 45 | 2023 | 9448 | 0.670 |
Why?
| Leukemia | 4 | 2021 | 208 | 0.630 |
Why?
| Mercaptopurine | 5 | 2017 | 15 | 0.590 |
Why?
| Disease-Free Survival | 11 | 2023 | 649 | 0.590 |
Why?
| Oncogene Proteins, Fusion | 5 | 2021 | 179 | 0.570 |
Why?
| Neoplasm Recurrence, Local | 4 | 2023 | 895 | 0.560 |
Why?
| Antineoplastic Agents | 7 | 2019 | 1967 | 0.540 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2016 | 92 | 0.530 |
Why?
| Preleukemia | 1 | 2015 | 2 | 0.520 |
Why?
| Molecular Targeted Therapy | 3 | 2021 | 355 | 0.510 |
Why?
| Drug Hypersensitivity | 3 | 2017 | 85 | 0.500 |
Why?
| Leukemia, Monocytic, Acute | 1 | 2014 | 4 | 0.490 |
Why?
| Sarcoma, Myeloid | 1 | 2014 | 4 | 0.490 |
Why?
| Neoplasm, Residual | 7 | 2023 | 103 | 0.480 |
Why?
| Prognosis | 13 | 2021 | 3424 | 0.480 |
Why?
| Infant | 32 | 2023 | 8254 | 0.470 |
Why?
| Bone Marrow Transplantation | 1 | 2014 | 244 | 0.440 |
Why?
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 16 | 0.430 |
Why?
| Adolescent | 37 | 2023 | 18364 | 0.430 |
Why?
| Acute Kidney Injury | 1 | 2019 | 705 | 0.420 |
Why?
| Erwinia | 2 | 2020 | 3 | 0.420 |
Why?
| Tumor Suppressor Proteins | 3 | 1999 | 287 | 0.410 |
Why?
| Chromosome Aberrations | 2 | 2022 | 136 | 0.410 |
Why?
| Recurrence | 9 | 2023 | 971 | 0.400 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 539 | 0.400 |
Why?
| Neutropenia | 2 | 2022 | 131 | 0.390 |
Why?
| Humans | 77 | 2023 | 118251 | 0.390 |
Why?
| Male | 53 | 2023 | 57474 | 0.390 |
Why?
| Stem Cell Transplantation | 3 | 2019 | 151 | 0.380 |
Why?
| Rhabdomyosarcoma | 1 | 2011 | 56 | 0.370 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 94 | 0.370 |
Why?
| Cell Cycle Proteins | 3 | 1999 | 563 | 0.370 |
Why?
| Sarcoma, Ewing | 1 | 2011 | 65 | 0.370 |
Why?
| Carrier Proteins | 3 | 1999 | 725 | 0.360 |
Why?
| Ploidies | 2 | 2019 | 18 | 0.350 |
Why?
| Catheter-Related Infections | 2 | 2022 | 60 | 0.340 |
Why?
| Core Binding Factor Alpha 2 Subunit | 3 | 2021 | 30 | 0.330 |
Why?
| Genes, Tumor Suppressor | 2 | 1999 | 77 | 0.330 |
Why?
| Cyclophosphamide | 4 | 2019 | 222 | 0.330 |
Why?
| Catheterization, Central Venous | 2 | 2022 | 95 | 0.320 |
Why?
| Female | 50 | 2023 | 61261 | 0.320 |
Why?
| Philadelphia Chromosome | 2 | 2018 | 15 | 0.310 |
Why?
| Survival Rate | 7 | 2021 | 1716 | 0.290 |
Why?
| Medication Adherence | 3 | 2017 | 554 | 0.280 |
Why?
| Vincristine | 4 | 2021 | 99 | 0.280 |
Why?
| Gene Deletion | 2 | 1998 | 359 | 0.280 |
Why?
| Trisomy | 2 | 2021 | 65 | 0.280 |
Why?
| Etoposide | 2 | 2019 | 149 | 0.270 |
Why?
| Antimetabolites, Antineoplastic | 2 | 2017 | 83 | 0.270 |
Why?
| Neoplasm Proteins | 2 | 2018 | 398 | 0.270 |
Why?
| Treatment Outcome | 12 | 2023 | 9319 | 0.250 |
Why?
| Young Adult | 14 | 2023 | 10731 | 0.250 |
Why?
| Anxiety | 3 | 2016 | 845 | 0.250 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 1999 | 58 | 0.240 |
Why?
| Medical Oncology | 4 | 2022 | 229 | 0.220 |
Why?
| Gene Rearrangement | 3 | 2019 | 141 | 0.220 |
Why?
| Polyethylene Glycols | 5 | 2020 | 575 | 0.210 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 59 | 0.210 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 2 | 0.210 |
Why?
| Induction Chemotherapy | 2 | 2019 | 59 | 0.210 |
Why?
| Adult | 22 | 2023 | 31324 | 0.210 |
Why?
| Central Venous Catheters | 1 | 2022 | 42 | 0.210 |
Why?
| Doxorubicin | 2 | 2022 | 301 | 0.210 |
Why?
| Lymphoma | 1 | 2023 | 179 | 0.200 |
Why?
| Prednisone | 2 | 2019 | 235 | 0.200 |
Why?
| Program Evaluation | 2 | 2017 | 838 | 0.200 |
Why?
| Lung Neoplasms | 1 | 2014 | 2216 | 0.200 |
Why?
| Translocation, Genetic | 2 | 2013 | 89 | 0.190 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2017 | 2057 | 0.180 |
Why?
| Risk Factors | 11 | 2022 | 8958 | 0.180 |
Why?
| Maintenance Chemotherapy | 2 | 2017 | 23 | 0.180 |
Why?
| Bacterial Infections | 1 | 2022 | 226 | 0.180 |
Why?
| Diploidy | 1 | 2019 | 11 | 0.180 |
Why?
| Immunocompromised Host | 1 | 2021 | 198 | 0.180 |
Why?
| Genes, p16 | 1 | 1999 | 18 | 0.170 |
Why?
| Prospective Studies | 9 | 2022 | 6443 | 0.170 |
Why?
| PAX5 Transcription Factor | 1 | 2019 | 12 | 0.170 |
Why?
| Hyperglycemia | 1 | 2023 | 313 | 0.170 |
Why?
| Antibodies, Bispecific | 1 | 2019 | 33 | 0.170 |
Why?
| Myelodysplastic Syndromes | 1 | 2020 | 118 | 0.170 |
Why?
| Chromosomes, Human, Pair 19 | 1 | 1998 | 25 | 0.170 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 1998 | 62 | 0.170 |
Why?
| Rituximab | 1 | 2019 | 153 | 0.160 |
Why?
| Mutagenesis | 1 | 1999 | 176 | 0.160 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 1998 | 72 | 0.160 |
Why?
| Patient Safety | 1 | 2021 | 281 | 0.160 |
Why?
| Quality of Life | 2 | 2021 | 2355 | 0.160 |
Why?
| Prostate-Specific Antigen | 2 | 2009 | 155 | 0.160 |
Why?
| Substance Withdrawal Syndrome | 1 | 2020 | 157 | 0.150 |
Why?
| Proto-Oncogenes | 1 | 1997 | 27 | 0.150 |
Why?
| Family Relations | 2 | 2016 | 84 | 0.150 |
Why?
| Oncologists | 1 | 2017 | 31 | 0.150 |
Why?
| Thionucleotides | 1 | 2017 | 34 | 0.150 |
Why?
| Apyrase | 1 | 2017 | 13 | 0.150 |
Why?
| Thioguanine | 1 | 2017 | 20 | 0.150 |
Why?
| Follow-Up Studies | 6 | 2021 | 4574 | 0.150 |
Why?
| Blast Crisis | 1 | 2016 | 19 | 0.140 |
Why?
| Depression | 2 | 2016 | 1133 | 0.140 |
Why?
| Carboxypeptidases A | 1 | 2016 | 2 | 0.140 |
Why?
| Retrospective Studies | 9 | 2023 | 12929 | 0.140 |
Why?
| Genomics | 2 | 2022 | 668 | 0.140 |
Why?
| Pediatricians | 1 | 2017 | 120 | 0.140 |
Why?
| Sepsis | 1 | 2022 | 531 | 0.140 |
Why?
| Mentors | 2 | 2017 | 165 | 0.140 |
Why?
| Mentoring | 1 | 2017 | 101 | 0.140 |
Why?
| Osteonecrosis | 1 | 2015 | 19 | 0.140 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 287 | 0.130 |
Why?
| Nausea | 1 | 2016 | 107 | 0.130 |
Why?
| Longitudinal Studies | 7 | 2016 | 2491 | 0.130 |
Why?
| Central Nervous System Neoplasms | 1 | 2017 | 128 | 0.130 |
Why?
| Adrenal Cortex Hormones | 1 | 2019 | 517 | 0.130 |
Why?
| Pancreatitis | 1 | 2016 | 105 | 0.130 |
Why?
| Mutation | 4 | 2022 | 3435 | 0.130 |
Why?
| Dexamethasone | 4 | 2021 | 319 | 0.130 |
Why?
| Fusion Proteins, bcr-abl | 2 | 2016 | 60 | 0.130 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 449 | 0.130 |
Why?
| Monitoring, Physiologic | 1 | 2017 | 268 | 0.130 |
Why?
| Bacteremia | 1 | 2016 | 161 | 0.120 |
Why?
| Cyclin-Dependent Kinase Inhibitor p15 | 3 | 1999 | 14 | 0.120 |
Why?
| Myeloid-Lymphoid Leukemia Protein | 2 | 2010 | 64 | 0.120 |
Why?
| Antigens, CD | 1 | 2017 | 457 | 0.120 |
Why?
| Flow Cytometry | 1 | 2018 | 1072 | 0.120 |
Why?
| Cross Infection | 1 | 2016 | 204 | 0.120 |
Why?
| Repressor Proteins | 1 | 1997 | 378 | 0.120 |
Why?
| Histone-Lysine N-Methyltransferase | 2 | 2010 | 99 | 0.120 |
Why?
| Immunotherapy | 1 | 2018 | 493 | 0.120 |
Why?
| Pediatrics | 3 | 2021 | 980 | 0.120 |
Why?
| DNA-Binding Proteins | 2 | 1998 | 1343 | 0.120 |
Why?
| Chromosomes, Human, Pair 21 | 1 | 2013 | 33 | 0.120 |
Why?
| Life Change Events | 1 | 2014 | 132 | 0.120 |
Why?
| Venous Thromboembolism | 1 | 2017 | 233 | 0.120 |
Why?
| Quality Improvement | 1 | 2021 | 962 | 0.120 |
Why?
| Self Report | 1 | 2017 | 698 | 0.110 |
Why?
| Transcription Factors | 2 | 1998 | 1567 | 0.110 |
Why?
| Leukemia, Megakaryoblastic, Acute | 1 | 2012 | 11 | 0.110 |
Why?
| Karyotyping | 3 | 2019 | 102 | 0.110 |
Why?
| Myeloproliferative Disorders | 1 | 2012 | 25 | 0.110 |
Why?
| Contraindications | 1 | 2012 | 86 | 0.100 |
Why?
| Arabinonucleosides | 1 | 2011 | 8 | 0.100 |
Why?
| Adenine Nucleotides | 1 | 2011 | 20 | 0.100 |
Why?
| Antibodies, Monoclonal | 1 | 2018 | 1279 | 0.100 |
Why?
| Cohort Studies | 5 | 2021 | 5078 | 0.100 |
Why?
| Prostatic Neoplasms | 2 | 2009 | 939 | 0.100 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2010 | 28 | 0.090 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 2010 | 19 | 0.090 |
Why?
| T-Lymphocytes | 1 | 2018 | 1770 | 0.090 |
Why?
| Pain | 1 | 2016 | 736 | 0.090 |
Why?
| Parents | 2 | 2016 | 1208 | 0.090 |
Why?
| Multivariate Analysis | 4 | 2015 | 1469 | 0.090 |
Why?
| Age Factors | 8 | 2019 | 2990 | 0.090 |
Why?
| Prostatectomy | 1 | 2009 | 99 | 0.080 |
Why?
| Neoplasm Metastasis | 1 | 2011 | 541 | 0.080 |
Why?
| Bloom Syndrome | 1 | 1988 | 1 | 0.080 |
Why?
| Juxtaglomerular Apparatus | 1 | 2007 | 1 | 0.080 |
Why?
| Gene Expression Regulation, Leukemic | 2 | 2016 | 49 | 0.080 |
Why?
| Polymerase Chain Reaction | 1 | 2010 | 1004 | 0.070 |
Why?
| Blood Coagulation | 1 | 2008 | 202 | 0.070 |
Why?
| Stress, Psychological | 1 | 2014 | 967 | 0.070 |
Why?
| Drug Administration Schedule | 2 | 2017 | 734 | 0.070 |
Why?
| Methotrexate | 2 | 2017 | 227 | 0.070 |
Why?
| Remission Induction | 2 | 2019 | 246 | 0.060 |
Why?
| Drug Monitoring | 2 | 2017 | 185 | 0.060 |
Why?
| Acute Disease | 2 | 2019 | 933 | 0.060 |
Why?
| Personal Satisfaction | 2 | 2017 | 183 | 0.060 |
Why?
| Administration, Oral | 2 | 2017 | 753 | 0.060 |
Why?
| Kidney Neoplasms | 1 | 2007 | 333 | 0.060 |
Why?
| Genetic Variation | 1 | 1988 | 912 | 0.060 |
Why?
| Disease Progression | 2 | 2021 | 2477 | 0.050 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2020 | 1237 | 0.050 |
Why?
| Risk | 5 | 2023 | 849 | 0.050 |
Why?
| Transcriptome | 2 | 2019 | 752 | 0.050 |
Why?
| Proto-Oncogene Proteins c-cbl | 1 | 2022 | 12 | 0.050 |
Why?
| Incidence | 2 | 2019 | 2413 | 0.050 |
Why?
| Exome | 1 | 2022 | 210 | 0.050 |
Why?
| Drug Therapy | 1 | 2021 | 76 | 0.050 |
Why?
| Diarrhea | 2 | 1999 | 180 | 0.050 |
Why?
| Risk Assessment | 3 | 2017 | 3043 | 0.050 |
Why?
| Bone Marrow | 1 | 2022 | 252 | 0.050 |
Why?
| Surveys and Questionnaires | 3 | 2017 | 4684 | 0.050 |
Why?
| Endocrine Glands | 1 | 1979 | 16 | 0.050 |
Why?
| Blood Cell Count | 1 | 1999 | 52 | 0.040 |
Why?
| Viral Load | 1 | 2021 | 406 | 0.040 |
Why?
| Chromosomes, Human | 1 | 2019 | 40 | 0.040 |
Why?
| Azacitidine | 1 | 2020 | 119 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2019 | 28 | 0.040 |
Why?
| Loss of Heterozygosity | 1 | 1999 | 40 | 0.040 |
Why?
| Mosaicism | 1 | 2019 | 62 | 0.040 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 164 | 0.040 |
Why?
| Interviews as Topic | 1 | 2021 | 593 | 0.040 |
Why?
| Genome-Wide Association Study | 2 | 2016 | 1318 | 0.040 |
Why?
| Infant, Newborn | 4 | 2019 | 5230 | 0.040 |
Why?
| Overweight | 1 | 2023 | 492 | 0.040 |
Why?
| United States | 4 | 2021 | 12488 | 0.040 |
Why?
| Disinfectants | 1 | 1999 | 33 | 0.040 |
Why?
| Sequence Deletion | 1 | 1999 | 169 | 0.040 |
Why?
| Chromosomes | 1 | 2019 | 87 | 0.040 |
Why?
| National Cancer Institute (U.S.) | 1 | 2018 | 43 | 0.040 |
Why?
| Hypertension | 1 | 2007 | 1199 | 0.040 |
Why?
| Escherichia coli O157 | 1 | 1998 | 31 | 0.040 |
Why?
| Feasibility Studies | 1 | 2021 | 746 | 0.040 |
Why?
| Methylation | 1 | 1998 | 204 | 0.040 |
Why?
| Community Participation | 1 | 1999 | 120 | 0.040 |
Why?
| Family | 1 | 2021 | 578 | 0.040 |
Why?
| Public Health Surveillance | 1 | 2017 | 57 | 0.040 |
Why?
| Erythrocyte Count | 1 | 2017 | 19 | 0.040 |
Why?
| Glucose | 1 | 2023 | 940 | 0.040 |
Why?
| Genetic Predisposition to Disease | 2 | 2017 | 2262 | 0.040 |
Why?
| Food-Drug Interactions | 1 | 2017 | 6 | 0.040 |
Why?
| Leucovorin | 1 | 2017 | 42 | 0.040 |
Why?
| Escherichia coli Infections | 1 | 1998 | 105 | 0.040 |
Why?
| Biopsy | 1 | 2021 | 1078 | 0.040 |
Why?
| Injections, Intramuscular | 1 | 2017 | 116 | 0.040 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 1997 | 51 | 0.040 |
Why?
| Career Mobility | 1 | 2017 | 65 | 0.040 |
Why?
| Dairy Products | 1 | 2017 | 31 | 0.040 |
Why?
| Water Purification | 1 | 1999 | 131 | 0.040 |
Why?
| Sulfonamides | 1 | 2020 | 444 | 0.040 |
Why?
| Cranial Irradiation | 1 | 2017 | 69 | 0.040 |
Why?
| Cerebrospinal Fluid | 1 | 2017 | 93 | 0.040 |
Why?
| Middle Aged | 10 | 2019 | 27510 | 0.040 |
Why?
| MEF2 Transcription Factors | 1 | 2016 | 57 | 0.040 |
Why?
| Infusions, Intravenous | 1 | 2017 | 379 | 0.040 |
Why?
| Qualitative Research | 1 | 2021 | 952 | 0.040 |
Why?
| Leukocyte Count | 1 | 2017 | 303 | 0.040 |
Why?
| Methyltransferases | 1 | 2017 | 61 | 0.040 |
Why?
| NIH 3T3 Cells | 1 | 2016 | 138 | 0.040 |
Why?
| Luciferases | 1 | 2016 | 142 | 0.040 |
Why?
| Methyl Ethers | 1 | 1996 | 8 | 0.040 |
Why?
| Breast Neoplasms | 5 | 1979 | 1957 | 0.030 |
Why?
| Anesthetics, Inhalation | 1 | 1996 | 13 | 0.030 |
Why?
| Ethers | 1 | 1996 | 17 | 0.030 |
Why?
| Bone Morphogenetic Protein 7 | 1 | 2015 | 10 | 0.030 |
Why?
| Fluorides | 1 | 1996 | 47 | 0.030 |
Why?
| Health Education | 1 | 1999 | 317 | 0.030 |
Why?
| Cytarabine | 1 | 2016 | 53 | 0.030 |
Why?
| Alternative Splicing | 1 | 2017 | 190 | 0.030 |
Why?
| Severity of Illness Index | 2 | 2017 | 2659 | 0.030 |
Why?
| Genotype | 3 | 2017 | 1870 | 0.030 |
Why?
| Intensive Care Units, Pediatric | 1 | 2016 | 157 | 0.030 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2016 | 200 | 0.030 |
Why?
| Disease Management | 1 | 2019 | 566 | 0.030 |
Why?
| Homeodomain Proteins | 1 | 1998 | 469 | 0.030 |
Why?
| DNA Methylation | 1 | 1999 | 501 | 0.030 |
Why?
| Aged | 9 | 2019 | 19594 | 0.030 |
Why?
| HEK293 Cells | 1 | 2017 | 625 | 0.030 |
Why?
| Biomarkers, Tumor | 1 | 2021 | 1056 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 1999 | 1157 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 410 | 0.030 |
Why?
| Algorithms | 1 | 2021 | 1522 | 0.030 |
Why?
| Blood Glucose | 1 | 2023 | 1936 | 0.030 |
Why?
| Income | 1 | 2014 | 173 | 0.030 |
Why?
| Marriage | 1 | 2014 | 108 | 0.030 |
Why?
| Behavior | 1 | 2014 | 94 | 0.030 |
Why?
| Psychomotor Agitation | 1 | 2014 | 71 | 0.030 |
Why?
| Demography | 1 | 2014 | 273 | 0.030 |
Why?
| Base Sequence | 1 | 2016 | 2148 | 0.030 |
Why?
| Case-Control Studies | 2 | 2016 | 3156 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2017 | 964 | 0.030 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2013 | 310 | 0.030 |
Why?
| Odds Ratio | 1 | 2015 | 993 | 0.030 |
Why?
| Aggression | 1 | 2014 | 184 | 0.030 |
Why?
| Nucleoside Transport Proteins | 1 | 2011 | 4 | 0.030 |
Why?
| Erythrocytes | 1 | 2017 | 619 | 0.030 |
Why?
| Time Factors | 2 | 2015 | 6368 | 0.030 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2011 | 69 | 0.030 |
Why?
| Regression Analysis | 1 | 2014 | 984 | 0.030 |
Why?
| Escherichia coli | 1 | 2015 | 757 | 0.020 |
Why?
| Mice | 2 | 2019 | 15446 | 0.020 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 180 | 0.020 |
Why?
| Bacteria | 1 | 2016 | 751 | 0.020 |
Why?
| Logistic Models | 1 | 2015 | 1896 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 1262 | 0.020 |
Why?
| Obesity | 1 | 2023 | 2715 | 0.020 |
Why?
| Prevalence | 1 | 2016 | 2321 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 4887 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 840 | 0.020 |
Why?
| Emotions | 1 | 2014 | 494 | 0.020 |
Why?
| Sister Chromatid Exchange | 1 | 1988 | 4 | 0.020 |
Why?
| Genetic Complementation Test | 1 | 1988 | 62 | 0.020 |
Why?
| Cell Fusion | 1 | 1988 | 51 | 0.020 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 74 | 0.020 |
Why?
| Protein C | 1 | 2008 | 42 | 0.020 |
Why?
| Antithrombins | 1 | 2008 | 51 | 0.020 |
Why?
| Water Microbiology | 2 | 1999 | 78 | 0.020 |
Why?
| Fibrinogen | 1 | 2008 | 150 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3567 | 0.020 |
Why?
| Genetic Markers | 1 | 1988 | 347 | 0.020 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 82 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2007 | 188 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 2008 | 412 | 0.020 |
Why?
| Rare Diseases | 1 | 2007 | 93 | 0.020 |
Why?
| Blood Pressure Determination | 1 | 2007 | 133 | 0.020 |
Why?
| Nephrectomy | 1 | 2007 | 162 | 0.020 |
Why?
| Animals | 2 | 2019 | 33152 | 0.020 |
Why?
| RNA, Messenger | 1 | 2011 | 2657 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2007 | 1681 | 0.010 |
Why?
| Cell Line | 1 | 1988 | 2693 | 0.010 |
Why?
| Estriol | 1 | 1979 | 6 | 0.010 |
Why?
| Menstruation | 1 | 1979 | 36 | 0.010 |
Why?
| Estrone | 1 | 1979 | 36 | 0.010 |
Why?
| Prolactin | 1 | 1979 | 96 | 0.010 |
Why?
| Bolivia | 1 | 1999 | 60 | 0.010 |
Why?
| Luteinizing Hormone | 1 | 1979 | 173 | 0.010 |
Why?
| Follicle Stimulating Hormone | 1 | 1979 | 216 | 0.010 |
Why?
| Restaurants | 1 | 1998 | 17 | 0.010 |
Why?
| Food Handling | 1 | 1998 | 48 | 0.010 |
Why?
| Swimming | 1 | 1998 | 46 | 0.010 |
Why?
| Progesterone | 1 | 1979 | 242 | 0.010 |
Why?
| Disease Transmission, Infectious | 1 | 1998 | 56 | 0.010 |
Why?
| Water Supply | 1 | 1998 | 71 | 0.010 |
Why?
| Meat | 1 | 1998 | 89 | 0.010 |
Why?
| Estradiol | 1 | 1979 | 473 | 0.010 |
Why?
| Halothane | 1 | 1996 | 5 | 0.010 |
Why?
| Population Surveillance | 1 | 1999 | 413 | 0.010 |
Why?
| Analysis of Variance | 1 | 1999 | 1288 | 0.010 |
Why?
| Feces | 1 | 1998 | 392 | 0.010 |
Why?
| Ovarian Neoplasms | 1 | 1978 | 420 | 0.010 |
Why?
| Pedigree | 3 | 1978 | 485 | 0.010 |
Why?
| Kidney | 1 | 1996 | 1351 | 0.010 |
Why?
| Aged, 80 and over | 1 | 1999 | 6541 | 0.000 |
Why?
| Nebraska | 2 | 1976 | 9 | 0.000 |
Why?
| New York | 2 | 1976 | 113 | 0.000 |
Why?
| Genes | 1 | 1978 | 227 | 0.000 |
Why?
| Genetic Linkage | 1 | 1978 | 321 | 0.000 |
Why?
| Oncogenic Viruses | 1 | 1976 | 3 | 0.000 |
Why?
| Apocrine Glands | 1 | 1976 | 4 | 0.000 |
Why?
| Genetic Techniques | 1 | 1976 | 60 | 0.000 |
Why?
| Pheochromocytoma | 1 | 1976 | 54 | 0.000 |
Why?
| Klinefelter Syndrome | 1 | 1976 | 53 | 0.000 |
Why?
| Syndrome | 1 | 1976 | 343 | 0.000 |
Why?
| Pregnancy | 2 | 1978 | 5671 | 0.000 |
Why?
| Statistics as Topic | 1 | 1976 | 307 | 0.000 |
Why?
| HLA Antigens | 1 | 1976 | 223 | 0.000 |
Why?
| Skin Diseases | 1 | 1976 | 125 | 0.000 |
Why?
| Sarcoma | 1 | 1976 | 137 | 0.000 |
Why?
| Abnormalities, Multiple | 1 | 1976 | 182 | 0.000 |
Why?
| Sex Factors | 1 | 1978 | 1765 | 0.000 |
Why?
| Thyroid Neoplasms | 1 | 1976 | 278 | 0.000 |
Why?
| Neoplasms | 2 | 1976 | 2160 | 0.000 |
Why?
| Melanoma | 1 | 1976 | 664 | 0.000 |
Why?
| Registries | 1 | 1976 | 1806 | 0.000 |
Why?
| Phenotype | 1 | 1976 | 2937 | 0.000 |
Why?
| Brain Neoplasms | 1 | 1976 | 1019 | 0.000 |
Why?
|
|
Maloney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|